Company Overview
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Why Investors Should Care
Generates a return on equity of 138.8%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $48.47M (-57.7% YoY); net profit $-170.37M.
- Trailing 12 Months Year-on-year growth — revenue -19.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -19.60% |
Stock Price Performance
| 1 Year: | +380.20% |
| 6 Months: | -68.38% |
| 3 Months: | -13.05% |
| 1 Month: | -13.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.69 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 138.8%.
CONS
- Trading 96.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GOSS Gossamer Bio, Inc. R2KPHARMA | 9.46 | -0.18 | $57.86M | 0.00% | - | 138.78% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 95.84M | 9.48M | 9.89M | 11.49M | 13.29M | 16.95M |
| Operating Income | -26.13M | -33.04M | -50.02M | -39.81M | -34.02M | -46.35M | -49.99M | -55.79M | -54.97M | -65.34M | -53.57M | -53.20M | -55.60M | -55.66M | -54.34M | -53.87M | -56.02M | -47.94M | -46.30M | -40.49M | -41.96M | 52.09M | -33.92M | -36.81M | -38.77M | -49.11M | -44.87M |
| Net Income | -26.04M | -32.73M | -49.41M | -38.79M | -32.61M | -44.50M | -48.50M | -54.70M | -54.07M | -66.87M | -57.81M | -57.64M | -59.83M | -60.25M | -57.78M | -56.47M | -59.36M | -49.16M | -42.50M | -40.01M | -41.93M | 49.23M | -30.80M | -36.64M | -38.27M | -48.22M | -46.66M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.87 | -1.00 | -0.80 | -0.78 | -0.80 | -0.80 | -0.76 | -0.74 | -0.65 | -0.52 | -0.45 | -0.21 | -0.19 | 0.22 | -0.14 | -0.16 | -0.17 | -0.21 | -0.20 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | 114.70M | 48.47M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 218.53M | 173.76M | 174.62M | 211.72M |
| Operating Income | -6.65M | -148.99M | -186.14M | -233.96M | - | -218.53M | -173.76M | -59.92M | -163.25M |
| EBITDA | - | - | - | - | - | -211.07M | -161.92M | -39.97M | -158.47M |
| Interest Expense | - | - | - | - | - | 13.88M | 13.51M | 11.52M | 10.99M |
| Pretax Income | - | - | - | - | - | -229.38M | -179.82M | -55.63M | -170.46M |
| Tax Provision | - | - | - | - | - | 0 | 0 | 893.00K | -88.00K |
| Net Income | -6.77M | -146.97M | -180.31M | -243.36M | - | -229.38M | -179.82M | -56.53M | -170.37M |
| Diluted EPS | - | - | -3.29 | -3.55 | - | -2.71 | -1.18 | -0.25 | -0.75 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 239.42M | 426.60M | 539.43M | 343.66M | 272.45M | 311.92M | 315.29M | 172.25M |
| Total Equity | -123.00K | -6.86M | -120.07M | 352.49M | 320.68M | 121.46M | 12.08M | 62.77M | 29.49M | -122.76M |
| Cash & Equivalents | - | - | 105.22M | 135.03M | 486.06M | 183.40M | 111.97M | 32.11M | 46.07M | 37.73M |
| Long Term Debt | - | - | - | 28.46M | 28.74M | 29.08M | 11.99M | 814.00K | 0 | - |
| Total Liabilities | - | - | 21.12M | 74.12M | 218.75M | 222.19M | 260.37M | 249.15M | 285.80M | 295.01M |
| Current Liabilities | - | - | 20.40M | 36.92M | 38.65M | 39.86M | 49.23M | 51.60M | 45.01M | 63.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.75M | -51.04M | -144.83M | -176.36M | -188.89M | -187.03M | -159.16M | -3.47M | -171.27M |
| Investing Cash Flow | - | -144.71M | -147.14M | 215.34M | -117.43M | -1.03M | -110.97M | 29.02M | 156.36M |
| Financing Cash Flow | 6.00M | 300.86M | 321.58M | 312.54M | 3.33M | 117.09M | 190.15M | -11.49M | 6.42M |
| Capital Expenditure | - | -3.49M | -2.97M | -1.50M | -1.55M | -410.00K | -0 | -0 | -79.00K |
| Free Cash Flow | - | -54.53M | -147.80M | -177.86M | -190.44M | -187.44M | -159.16M | -3.47M | -171.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -52.2% | -336.8% |
| Net Margin % | - | - | - | - | - | - | - | -49.3% | -351.5% |
| ROE % | 98.7% | 122.4% | -51.2% | -75.9% | - | -1,899.3% | -286.5% | -191.7% | 138.8% |
| ROCE % | - | -68.0% | -47.8% | -46.7% | - | -97.9% | -66.7% | -22.2% | -150.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Shaw D.E. & Co., Inc. | 8.37% | 511.99K | $4.77M |
| 2 | 683 Capital Management LLC | 8.01% | 489.99K | $4.56M |
| 3 | DeepCurrents Investment Group, LLC | 7.70% | 470.81K | $4.38M |
| 4 | Context Capital Management, LLC | 5.92% | 361.83K | $3.37M |
| 5 | Worth Venture Partners, Llc | 5.11% | 312.72K | $2.91M |
| 6 | AQR Capital Management, LLC | 3.19% | 195.38K | $1.82M |
| 7 | GSA Capital Partners LLP | 3.06% | 187.34K | $1.74M |
| 8 | Wolverine Asset Management, LLC | 2.64% | 161.18K | $1.50M |
| 9 | Renaissance Technologies, LLC | 2.38% | 145.37K | $1.35M |
| 10 | Kalehua Capital Management LLC | 2.28% | 139.37K | $1.30M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GOSS
Gossamer Bio Inc (GOSS) Stock Price Target & Forecast - TradingKey
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE9NRl9DM1hGWS1wZjQyQmdoMC13MHM0ZUd2MnRFM0E3RlhRTXJlVU5NMkNSNVZJYWFuNHVkUjN5elVGVUx1LVA0bkI0bkJSeUhRc3BMTmxGbU5zNmJJY3hrSGtPdUUwQQ?oc=5" target="_blank">Gossamer Bio Inc (GOSS) Stock…
Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNbEtTbzR3TXJDTjV4OGw0UndIdmlHWHBoVFp1SDVWNE51WjBnU040cHFReDJNVUtocjVuczh3d2FwektmeTNsYjRoVEU3SS12Wm55MnRwY1FSYU5MbnZnbUE5bjNVLTZ4aEtqNm5BU1h2bWJ6cThIZmxqdmdNWWpLd0haMVcydjZZTUUydV…
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5uQlZsS1l3RWFDbUlTLVZxWEp2VGlrZmJtbk9hcGRvSHhXbXl6Z3hFbnBERGVpMFlxT29EaGVfZnYxa3NPS0dDQ2NBS2dlZ3ZVWEtZWVBzZU5zY1E?oc=5" target="_blank">GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS)</…
Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPMDZmaDFXUEQ1a0hmRFczaHVEdWRWQmc1bVpob25GTkw2a0NscEJzdUpZUTYxVThVckhQUGNiWHZ1TU9rQldUU19OdUlUYVRZY2ZvQXcwQ0VLWWFyZVQwa09jU2ZCUjFJMkxMTDJtRkFvNGZFUGxOOGZwWEV6VGZ0RnFmcGsxYUNMRWU1Wm…
Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNMnVBQm5ySkRuQ2h4UGNzVnYxVHZjRTRUZ1ZBakRxSmRicjhsR0NMZC1QM1RLS1VSTDBLMlRHY0dOeG9SUEhBcjZ1amtYaVIyYTBycDNzcy1rSGE0Y25COTJ3eC1tQXNxVkJPdmY5eFBMQmFGZDFjenFwSzRrQmRtUjVBbGNvRFo2T0tfS2…
Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQR1pxQ3JDWm1kVG1PaE9qN0hQYXlheUo5TGJ6bmQwX3hfZV90ZHF0ZHROUl9oNWZRTkN4Q1p4TjBTSkZsakpadGhDQmlFeVJwVk53YUZBNElnNVRzM3JfbEhqUEdrak5TaFZjUVNRVEZnT0VWOUJQWnhkUG9PVFE1dFBsNDBUWW5Kc0VjeE…
GOSS — Frequently Asked Questions
What is the current share price of Gossamer Bio, Inc. (GOSS)?
As of 2026-10-22 16:30 PDT, Gossamer Bio, Inc. (GOSS) trades at $9.46 on NasdaqGS. Its 52-week range is $1.92 to $303.20.
What is the market capitalisation of GOSS?
Gossamer Bio, Inc. (GOSS) has a market capitalisation of $57.86M on NasdaqGS.
What is the P/E ratio of GOSS?
GOSS trades at a trailing price-to-earnings (P/E) ratio of -0.18. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is -55.89.
What is the return on equity (ROE) of GOSS?
GOSS has a return on equity (ROE) of 138.78%.
Is GOSS a good stock to buy?
This page provides a data-driven analysis of Gossamer Bio, Inc. (GOSS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.